About Coya Therapeutics
Coya Therapeutics (NASDAQ:COYA) focuses on developing innovative therapies aimed at combating a wide range of autoimmune, neurodegenerative, and aging-related diseases. By harnessing the power of regulatory T cells (Tregs) and leveraging advanced biotechnological processes, Coya Therapeutics aims to pave new pathways in the treatment of conditions like ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, and systemic lupus erythematosus (SLE). Central to their mission is the commitment to advancing clinical research, with several key projects in various stages of development aimed at unlocking the therapeutic potential of Tregs. Their objectives include not only advancing the science behind autoimmune and neurodegenerative disease treatments but also improving the quality of life for patients suffering from these challenging conditions.
Snapshot
Operations
Produtos e/ou serviços de Coya Therapeutics
- Development of therapeutic treatments focused on neurodegenerative diseases such as ALS and Alzheimer's.
- Research on anti-inflammatory therapeutics for autoimmune disorders.
- Innovative approaches to enhancing the bioavailability of treatments for better patient outcomes.
- Collaborations with academic institutions for advanced research in neurology and immunology.
- Engagement in clinical trials to validate the efficacy and safety of new drugs and therapies.
- Leveraging proprietary technology platforms to discover novel therapeutic targets.
equipe executiva do Coya Therapeutics
- Dr. Howard H. Berman Ph.D.Co-Founder & Executive Chair
- Dr. Arun Swaminathan Ph.D.CEO & Director
- Dr. Fred Grossman D.O., FAPAPresident & Chief Medical Officer
- Mr. David S. SnyderCFO & COO
- Mr. Aaron Thome Ph.D.Head of Neuroinflammation Platform
- Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory
- Ms. Karen King M.S.Senior VP of Program Management & Clinical Operations